Organisation paid for research Program year 2025 Source: CMS Open Payments

The Board of Trustees of the Leland

Neither a doctor nor a teaching hospital

Research payments

$5,010,455

331 payments

Through program year 2025, The Board of Trustees of the Leland is reported as receiving $5,010,455 in research payments, across 331 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$849,028	88
2024	Research	$345,173	43
2023	Research	$395,988	49
2022	Research	$1,676,489	106
2021	Research	$542,658	19
2020	Research	$452,285	17
2019	Research	$748,834	9

Breakdown

Who paid Research payments · program years 2019–2025

Boehringer Ingelheim Pharmaceuticals, Inc. $1,377,505 19 payments
AbbVie, Inc. $1,003,382 167 payments
Hoffmann-La Roche Limited $562,192 11 payments
Genentech, Inc. $495,017 18 payments
Janssen Research & Development, LLC $487,836 7 payments
Roche Products Limited $303,799 18 payments
Edwards Lifesciences Corporation $263,116 28 payments
Abbott Laboratories $185,046 18 payments
Bayer HealthCare Pharmaceuticals Inc. $112,690 13 payments
Jazz Pharmaceuticals Inc. $106,752 1 payment

Studies the money was for Research payments · program years 2019–2025

Morpheus Breast $529,545 7 payments
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. $377,368 4 payments
To evaluate efficacy of combined blockage of infla $300,000 2 payments
PH Ia Ib Personalized Cancer Vaccine Atezolizumabb $299,672 13 payments
Validation of a Highly Sensitive Lung Ultrasound I $225,000 2 payments
Morpheus UC $203,064 13 payments
Hypotension Prediction Index Study (HPI Study) $177,335 12 payments
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed;Refractory Acute Lymphoblastic Leukemia or Relapsed;Refractory Lymphoblastic Lymphoma $148,119 1 payment
Glaucoma Biorepository $114,092 1 payment
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation $108,868 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.